Oral metronomic scheduling of anticancer therapy-based treatment compared to existing standard of care in locally advanced oral squamous cell cancers: A matched-pair analysis.
Indian J Cancer
;
2013 Apr-June; 50(2): 135-141
Article
in English
| IMSEAR
| ID: sea-148638
ABSTRACT
CONTEXT Head and neck cancers in developing countries present with advanced disease, compounded by poor access to tertiary care centers. AIM:
We evaluated oral metronomic scheduling of anticancer therapy (MSAT) in advanced operable oral cancers, in conjunction with standard therapy. SETTINGS ANDDESIGN:
This was a retrospective matched‑pair analysis carried out in a tertiary referral cancer center. MATERIALS ANDMETHODS:
Advanced operable oral cancer patients having a waiting period for surgery > 3 weeks were administered MSAT. Patients then underwent standard therapy (surgery +/‑ adjuvant radiation/chemoradiation) as warranted by the disease, followed by MSAT maintenance therapy. Outcomes of the MSAT group were compared with stage‑matched controls with similar waiting periods. STATISTICALANALYSIS:
Survivals were found using the Kaplan‑Meier method and compared between groups using the log rank test.RESULTS:
Response was seen in 75% of 32 patients. Two‑year disease‑free survivals (DFS) in MSAT and control groups were 86.5 and 71.6%, respectively. Two‑year DFS in MSAT group who received at least three months of MSAT was 94.6% (P = 0.03).CONCLUSIONS:
Oral MSAT is an economical, effective, and safe adjuvant therapy for oral cancers. It has the potential for preventing progression of the disease and improving DFS.
Full text:
Available
Index:
IMSEAR (South-East Asia)
Main subject:
Female
/
Humans
/
Male
/
Mouth Neoplasms
/
Carcinoma, Squamous Cell
/
Retrospective Studies
/
Cisplatin
/
Combined Modality Therapy
/
Disease-Free Survival
/
Standard of Care
Type of study:
Observational study
Language:
English
Journal:
Indian J Cancer
Year:
2013
Type:
Article
Similar
MEDLINE
...
LILACS
LIS